This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2002;162:1806-1808.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

VENOUS THROMBOEMBOLISM (VTE) is a common disease, with an average annual incidence of over 1 per 1000.¹ Venous thromboembolism also is a potentially lethal disease, mostly owing to pulmonary embolism (PE). Almost one quarter of all PE cases present as essentially sudden death, with a 1-week survival of only 71%.² Patients with deep vein thrombosis (DVT) often experience serious and costly long-term complications. Almost 30% of patients develop serious venous stasis syndrome within 10 years^3-4 at an estimated cost of over $4000 per episode in 1997 dollars.⁵ To improve survival and prevent complications, the incidence of VTE must be reduced.

Of the total burden of VTE occurring in the community, 50% arises in either hospitalized or recently hospitalized patients.⁶ The incidence of VTE is over 100-fold higher among hospitalized patients compared with community residents.⁷ Of all independent risk factors for VTE, surgery conveys the highest risk,⁸ and major orthopedic leg . . . [Full Text of this Article]

PHARMACOLOGIC PROPERTIES OF FONDAPARINUX AND CLINICAL STUDIES


CONCLUSIONS


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Fondaparinux Requires Further Study Before Firm Recommendation
Steven J. Hughes
Arch Intern Med. 2003;163(4):498.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: A Meta-analysis of 4 Randomized Double-blind Studies
Alexander G. G. Turpie, Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen, and for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies
Arch Intern Med. 2002;162(16):1833-1840.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

New Antithrombotic Drugs: Potential for Use in Oncology
Levine
JCO 2009;27:4912-4918.
ABSTRACT | FULL TEXT  

Fondaparinux Requires Further Study Before Firm Recommendation
Hughes
Arch Intern Med 2003;163:498-498.
FULL TEXT